NCT06585410 2026-04-22
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3 Recruiting
Clinical Trials
14 trialsNCT02621021 2026-04-20
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06947928 2026-04-17
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
Phase 2/3 Recruiting
NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT05047094 2026-04-06
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT05727904 2026-04-03
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Iovance Biotherapeutics, Inc.
Phase 3 Recruiting
NCT07510061 2026-04-03
ICARUS
University of Thessaly
Phase NA Recruiting
NCT04562129 2026-04-01
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05070403 2026-04-01
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05651828 2026-04-01
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
NCT06298734 2026-04-01
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
Fred Hutchinson Cancer Center
Phase NA Recruiting
NCT06875609 2026-03-30
ctDNA in Cutaneous Squamous Cell Carcinoma
Massachusetts Eye and Ear Infirmary
Recruiting
NCT06060613 2026-03-27
Agni-01
Obsidian Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07349940 2026-03-27
MEL
Institute of Health Information and Statistics of the Czech Republic
Phase NA Recruiting